Showing results (191-200 of 342) with videos related to
Sort By:
Pageof 35
Chest|February 3, 2016
Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in Patients With PneumoniaNathan C Dean, Paula P Griffith, Jeffrey S Sorensen, et al.Lung Cancer (Amsterdam, Netherlands)|January 7, 2014
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancerBritta Weber, Henrik Hager, Boe S Sorensen, et al.Scandinavian Journal of Clinical and Laboratory Investigation|March 1, 2016
Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkersBirgitte Sandfeld-Paulsen, Christina Demuth, Birgitte H Folkersen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2002
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E)K Schreiber, A B Otura, L P Ryder, et al.BMC Cancer|April 30, 2014
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assaysBritta Weber, Peter Meldgaard, Henrik Hager, et al.Oncogenesis|April 4, 2017
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cellsK R Jakobsen, C Demuth, A T Madsen, et al.Journal of the American Chemical Society|August 17, 2006
Triphenylene analogues with B2N2C2 cores: synthesis, structure, redox behavior, and photophysical propertiesCory A Jaska, David J H Emslie, Michael J D Bosdet, et al.Cancers|March 29, 2023
Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung CancerTrine V Larsen, Nina Dybdal, Tina F Daugaard, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2008
Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosisS Bramow, J C Faber-Rod, C Jacobsen, et al.Neurology|May 5, 2010
Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic responseD Hesse, M Krakauer, H Lund, et al.Pageof 35